Cargando…

Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma

PURPOSE: To investigate the role of intensity modulated proton therapy (IMPT) for advanced hepatocellular carcinoma in comparison with volumetric modulated arc therapy (VMAT). METHODS: An in-silico planning study was performed on 20 patients. The prescription dose was 60Gy in 6 fractions. Patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Cozzi, Luca, Comito, Tiziana, Fogliata, Antonella, Franzese, Ciro, Tomatis, Stefano, Scorsetti, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089420/
https://www.ncbi.nlm.nih.gov/pubmed/30102749
http://dx.doi.org/10.1371/journal.pone.0201992
_version_ 1783347016518074368
author Cozzi, Luca
Comito, Tiziana
Fogliata, Antonella
Franzese, Ciro
Tomatis, Stefano
Scorsetti, Marta
author_facet Cozzi, Luca
Comito, Tiziana
Fogliata, Antonella
Franzese, Ciro
Tomatis, Stefano
Scorsetti, Marta
author_sort Cozzi, Luca
collection PubMed
description PURPOSE: To investigate the role of intensity modulated proton therapy (IMPT) for advanced hepatocellular carcinoma in comparison with volumetric modulated arc therapy (VMAT). METHODS: An in-silico planning study was performed on 20 patients. The prescription dose was 60Gy in 6 fractions. Patients were planned with abdominal compression. IMPT plans were optimized with or without the inclusion of CT calibration (3%) and isocenter positioning (2,4,6mm) uncertainties. Plan robustness was appraised comparing rubust optimized plans vs standard plans and also in terms of the worst-case scenario. VMAT plans were optimized for 10FFF photon beams using 2 partial arcs. RESULTS: Target coverage was fully achieved by both VMAT and IMPT plans with a significant improvement in homogeneity (~25%) with IMPT. Integral dose was reduced of ~60% with IMPT while the conformality of the dose distributions was similar among techniques. The sparing of the organs at risk was strongly improved with IMPT although all clinical objectives were met for both techniques. The inclusion of the uncertainties in the optimization lead to some deterioration in the target dose homogeneity (from 40 to 80% worse with 4 or 6mm position uncertainty) while none of the coverage parameters or OAR objective was violated. The worst-case scenario analysis demonstrated the risk of a major target underdosage only in the case of the most extreme errors (6mm) with D(98%) in average ~12% lower than the threshold. CONCLUSION: IMPT with the support of abdominal compression, can be considered a viable solution also for advanced hepatocellular carcinoma patients. Great care shall be put in the minimization of the residual respiration and positioning uncertainties but the dosimetric advantage for organs at risk and the relative robustness on target coverage are promising factors.
format Online
Article
Text
id pubmed-6089420
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-60894202018-08-30 Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma Cozzi, Luca Comito, Tiziana Fogliata, Antonella Franzese, Ciro Tomatis, Stefano Scorsetti, Marta PLoS One Research Article PURPOSE: To investigate the role of intensity modulated proton therapy (IMPT) for advanced hepatocellular carcinoma in comparison with volumetric modulated arc therapy (VMAT). METHODS: An in-silico planning study was performed on 20 patients. The prescription dose was 60Gy in 6 fractions. Patients were planned with abdominal compression. IMPT plans were optimized with or without the inclusion of CT calibration (3%) and isocenter positioning (2,4,6mm) uncertainties. Plan robustness was appraised comparing rubust optimized plans vs standard plans and also in terms of the worst-case scenario. VMAT plans were optimized for 10FFF photon beams using 2 partial arcs. RESULTS: Target coverage was fully achieved by both VMAT and IMPT plans with a significant improvement in homogeneity (~25%) with IMPT. Integral dose was reduced of ~60% with IMPT while the conformality of the dose distributions was similar among techniques. The sparing of the organs at risk was strongly improved with IMPT although all clinical objectives were met for both techniques. The inclusion of the uncertainties in the optimization lead to some deterioration in the target dose homogeneity (from 40 to 80% worse with 4 or 6mm position uncertainty) while none of the coverage parameters or OAR objective was violated. The worst-case scenario analysis demonstrated the risk of a major target underdosage only in the case of the most extreme errors (6mm) with D(98%) in average ~12% lower than the threshold. CONCLUSION: IMPT with the support of abdominal compression, can be considered a viable solution also for advanced hepatocellular carcinoma patients. Great care shall be put in the minimization of the residual respiration and positioning uncertainties but the dosimetric advantage for organs at risk and the relative robustness on target coverage are promising factors. Public Library of Science 2018-08-13 /pmc/articles/PMC6089420/ /pubmed/30102749 http://dx.doi.org/10.1371/journal.pone.0201992 Text en © 2018 Cozzi et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Cozzi, Luca
Comito, Tiziana
Fogliata, Antonella
Franzese, Ciro
Tomatis, Stefano
Scorsetti, Marta
Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma
title Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma
title_full Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma
title_fullStr Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma
title_full_unstemmed Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma
title_short Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma
title_sort critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089420/
https://www.ncbi.nlm.nih.gov/pubmed/30102749
http://dx.doi.org/10.1371/journal.pone.0201992
work_keys_str_mv AT cozziluca criticalappraisalofthepotentialroleofintensitymodulatedprotontherapyinthehypofractionatedtreatmentofadvancedhepatocellularcarcinoma
AT comitotiziana criticalappraisalofthepotentialroleofintensitymodulatedprotontherapyinthehypofractionatedtreatmentofadvancedhepatocellularcarcinoma
AT fogliataantonella criticalappraisalofthepotentialroleofintensitymodulatedprotontherapyinthehypofractionatedtreatmentofadvancedhepatocellularcarcinoma
AT franzeseciro criticalappraisalofthepotentialroleofintensitymodulatedprotontherapyinthehypofractionatedtreatmentofadvancedhepatocellularcarcinoma
AT tomatisstefano criticalappraisalofthepotentialroleofintensitymodulatedprotontherapyinthehypofractionatedtreatmentofadvancedhepatocellularcarcinoma
AT scorsettimarta criticalappraisalofthepotentialroleofintensitymodulatedprotontherapyinthehypofractionatedtreatmentofadvancedhepatocellularcarcinoma